CVE:BCT

BriaCell Therapeutics Competitors

C$4.00
-0.50 (-11.11 %)
(As of 04/14/2021 03:58 PM ET)
Add
Compare
Today's Range
C$4.00
Now: C$4.00
C$4.41
50-Day Range
C$4.08
MA: C$4.85
C$8.00
52-Week Range
C$3.70
Now: C$4.00
C$14.00
Volume47,271 shs
Average Volume10,068 shs
Market CapitalizationC$3.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

BriaCell Therapeutics (CVE:BCT) Vs. CTX, KNE, GSD, PAS, NSP, and MPH

Should you be buying BCT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to BriaCell Therapeutics, including Crescita Therapeutics (CTX), Kane Biotech (KNE), Devonian Health Group (GSD), Pascal Biosciences (PAS), Naturally Splendid Enterprises (NSP), and Medicure (MPH).

Crescita Therapeutics (TSE:CTX) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Crescita Therapeutics and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.11C$41,296.00C$0.00420.00
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.29

Crescita Therapeutics has higher revenue and earnings than BriaCell Therapeutics. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Crescita Therapeutics and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Crescita Therapeutics and BriaCell Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
BriaCell Therapeutics0000N/A

Summary

Crescita Therapeutics beats BriaCell Therapeutics on 3 of the 3 factors compared between the two stocks.

Kane Biotech (CVE:KNE) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Kane Biotech and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kane Biotech and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kane BiotechN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Kane Biotech and BriaCell Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kane Biotech0000N/A
BriaCell Therapeutics0000N/A

Summary

Kane Biotech beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

Devonian Health Group (CVE:GSD) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Earnings and Valuation

This table compares Devonian Health Group and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Devonian Health GroupC$1.59 million15.20C$-4,457,184.00C($0.05)-5.42
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Devonian Health Group. Devonian Health Group is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Devonian Health Group and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Devonian Health GroupN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Devonian Health Group and BriaCell Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Devonian Health Group0000N/A
BriaCell Therapeutics0000N/A

Summary

Devonian Health Group beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Pascal Biosciences and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-4.32
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.29

Pascal Biosciences is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pascal Biosciences and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pascal Biosciences and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
BriaCell Therapeutics0000N/A

Naturally Splendid Enterprises (CVE:NSP) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Naturally Splendid Enterprises and BriaCell Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Naturally Splendid Enterprises0000N/A
BriaCell Therapeutics0000N/A

Profitability

This table compares Naturally Splendid Enterprises and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Naturally Splendid EnterprisesN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares Naturally Splendid Enterprises and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Naturally Splendid EnterprisesC$2.03 million6.45C$-9,371,678.00C($0.04)-1.40
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Naturally Splendid Enterprises. Naturally Splendid Enterprises is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Naturally Splendid Enterprises beats BriaCell Therapeutics on 2 of the 3 factors compared between the two stocks.

Medicure (CVE:MPH) and BriaCell Therapeutics (CVE:BCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Medicure and BriaCell Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedicureC$12.71 million1.30C$-16,188,599.00C($1.55)-1.02
BriaCell TherapeuticsN/AN/AN/AC($3.10)-1.29

BriaCell Therapeutics has lower revenue, but higher earnings than Medicure. BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Medicure and BriaCell Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
BriaCell Therapeutics0000N/A

Profitability

This table compares Medicure and BriaCell Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedicureN/AN/AN/A
BriaCell TherapeuticsN/AN/AN/A

Summary

Medicure beats BriaCell Therapeutics on 3 of the 3 factors compared between the two stocks.


BriaCell Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
CTX
Crescita Therapeutics
0.6$0.84-1.2%C$17.34 millionC$15.64 million420.00News Coverage
KNE
Kane Biotech
0.4$0.16-0.0%C$14.12 millionC$1.34 million-4.57Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.10-5.3%C$12.70 millionN/A-4.32Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.06-8.3%C$11.06 millionC$2.03 million-1.40Gap Up
MPH
Medicure
0.7$1.58-1.3%C$10.80 millionC$12.71 million-1.02
BTI
Bioasis Technologies
0.7$0.39-1.3%C$10.16 millionC$4.12 million35.00
HEM
Hemostemix
0.6$0.45-2.2%C$9.07 millionN/A-2.68Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.37-1.4%C$6.94 millionC$5.60 million6.76News Coverage
Gap Down
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00Gap Up
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$45.95-3.2%C$0.00C$267.59 million50.49News Coverage
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66News Coverage
Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.